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Abstract The red wine polyphenol resveratrol boosts
endothelium-dependent and -independent vasorelaxations.
The improvement of endothelial function by resveratrol is
largely attributable to nitric oxide (NO) derived from
endothelial NO synthase (eNOS). By stimulating eNOS
expression, eNOS phosphorylation and eNOS deacetyla-
tion, resveratrol enhances endothelial NO production. By
upregulating antioxidant enzymes (superoxide dismutase,
catalase and glutathione peroxidase) and suppressing the
expression and activity of NADPH oxidases, resveratrol
inhibits superoxide-mediated NO inactivation. Some resver-
atrol effects are mediated by sirtuin 1 (SIRT1) or estrogen
receptors, respectively.
Introduction
Resveratrol is a polyphenol phytoalexin present in a variety
of plant species, including white hellebore (Veratrum
grandiflorum O. Loes), Polygonum cuspidatum, grapes,
peanuts and mulberries [1–3]. Resveratrol attracted little
interest until 1992 when it was postulated to explain some
of the cardioprotective effects of red wine. Since then,
accumulating reports have shown that resveratrol can
prevent or slow the progression of a wide variety of
diseases, including cancer, cardiovascular disease, ischemic
injuries and Alzheimer’s disease. The compound has also
been shown to extend the lifespan of various organisms
from yeast to vertebrates [1, 2, 4].
Resveratrol induces vasorelaxation in vitro
In organ chambers in vitro, resveratrol inhibits the
contractile response to noradrenaline [5] and causes
relaxation of the phenylephrine-precontracted rat aorta [5].
The vasorelaxant activity of resveratrol has also been
observed in the mesenteric and uterine arteries of guinea
pigs [6], and in porcine coronary arteries [7]. Both
endothelium-dependent and endothelium-independent
mechanisms are involved in resveratrol-induced vascular
relaxation [2]. The endothelium-dependent vasorelaxation
is largely attributable to NO, whereas the endothelium-
independent relaxation is likely to be mediated by some ion
channels including voltage-gated K
+ channels, big Ca
2+-
activated K
+ channels or voltage-gated Ca
2+ channels
[8, 9].
Resveratrol improves endothelial function in vivo
Endothelial dysfunction (characterized as an impairment of
endothelium-dependent relaxation) is an early event in the
development of atherosclerosis and is present even before
structural changes occur in the vasculature. All major risk
factors for atherosclerosis such as hyperlipidemia, diabetes,
hypertension and smoking are associated with endothelial
dysfunction [10].
Oral treatment with resveratrol results in the enhance-
ment of agonist-stimulated, endothelium-dependent relaxa-
tions, demonstrating its therapeutic potential. Such an
improvement in endothelial function has been shown in
hypertensive rats [11–13], diabetic rats and mice [14, 15]
and hypercholesterolemic rabbits [16].
In the current issue of Cardiovascular Drugs and
Therapy, Soylemez et al. provide evidence that in vivo
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responsiveness in healthy rats [17]. This indicates the
potential of resveratrol for health promotion and disease
prevention.
Resveratrol enhances NO synthesis by modulating
eNOS expression and activity
The resveratrol-induced improvement of endothelial func-
tion is largely attributable to nitric oxide (NO) derived from
endothelial NO synthase (eNOS). Resveratrol enhances NO
synthesis and decreases NO inactivation (Fig. 1).
Resveratrol enhances eNOS expression We have shown
that resveratrol [18]a n dr e dw i n er i c hi nr e s v e r a t r o l[ 19]
enhance the expression of eNOS in human endothelial
cells. Resveratrol is known to be an activator of the
protein deacetylase Sirtuin 1 (SIRT1) [20]. The effect of
r e s v e r a t r o lo ne N O Se x p r e s s i o ni sl i k e l yt ob em e d i a t e db y
SIRT1. Calorie restriction leads to the enhanced expres-
sion of SIRT1 and eNOS upregulation [21]; the
endothelium-specific overexpression of SIRT1 results in
an increase in eNOS expression in mice [22]. In human
coronary arterial endothelial cells, resveratrol-induced
eNOS expression can be prevented by the knockdown of
SIRT1 [23].
Resveratrol enhances eNOS phosphorylation The treatment
of endothelial cells with nanomolar concentrations of
resveratrol leads to the rapid phosphorylation of eNOS at
serine 1177 and an increase in eNOS enzymatic activity [24,
25]. In human endothelial cells, this effect seems to be
mediated by the estrogen receptor ERα that is localized in a
“signalsome complex” within caveolae [25]. Resveratrol
rapidly activates ERα in caveolae, leading to eNOS
activation via the activation of Gα, Cav-1, Src and MAPK
(ERK1/2) in a manner similar to that elicited by estradiol
[25]. In addition, a recent study demonstrated that resveratrol
prevented hyperglycemia-induced endothelial dysfunction
via the activation of adenosine monophosphate-activated
protein kinase (AMPK) [26].
Resveratrol decreases eNOS acetylation SIRT1 deacety-
lates ε-acetyllysine residues in histones and many non-
histone proteins including eNOS. SIRT1 deacetylates eNOS
at lysine residues in the calmodulin-binding domain and
thereby stimulates eNOS activity. The short-term treatment
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Fig. 1 Mechanisms of resveratrol-induced improvement of vascular
function. Resveratrol induces vasorelaxation through both
endothelium-dependent and -independent mechanisms. Resveratrol
increases endothelial NO production by SIRT1-dependent eNOS
upregulation, SIRT1-dependent eNOS deacetylation and estrogen
receptor ERα-dependent, ERK1/2-mediated eNOS phosphorylation.
By decreasing the expression and activity of vascular NADPH
oxidases (NOX) and enhancing the expression of superoxide
dismutases (SOD), catalase and glutathione peroxidases, resveratrol
decreases superoxide-mediated NO inactivation. The resulting eleva-
tion in NO bioactivity is likely to mediate the endothelium-dependent
relaxation. Ion channels seem to be involved in the endothelium-
independent effects of resveratrol
426 Cardiovasc Drugs Ther (2009) 23:425–429of endothelial cells with resveratrol leads to SIRT1
activation and eNOS deacetylation. Resveratrol-induced
endothelial NO production can be significantly reduced by
siRNA-mediated SIRT1 knockdown [27].
Resveratrol reduces superoxide-mediated
NO breakdown
NO can be rapidly inactivated by superoxide. There is
evidence that resveratrol can reduce vascular superoxide
levels through multiple mechanisms (see below). This
enhances NO bioavailability and is likely to contribute to
the improvement of endothelial function by resveratrol.
The direct antioxidant activity of resveratrol is poor As a
polyphenolic compound, resveratrol has been shown to be a
scavenger of hydroxyl, superoxide and metal-induced
radicals [2]. However, the direct antioxidant effects of
resveratrol are rather poor; resveratrol is less potent than
other well-established antioxidants such as ascorbate and
cysteine [2]. In addition, resveratrol is ineffective at
scavenging superoxide anions generated enzymatically by
a hypoxanthine/xanthine oxidase (HX/XO) system and/or
inhibiting XO [28, 29]. Therefore, the direct antioxidant
effects of resveratrol are likely to play only a secondary role
in vasoprotection, and the protective properties of resver-
atrol are more likely to be attributable to effects on pro- and
antioxidatives gene products.
Resveratrol inhibits NADPH oxidase activity and expres-
sion Reactive oxygen species (ROS) can be produced by
several enzyme systems in the vascular wall with NADPH
oxidases being the predominant source of ROS [30]. In the
current issue of Cardiovascular Drugs and Therapy,
Soylemez et al. demonstrate that resveratrol supplementa-
tion attenuates angiotensin II- or NADPH-induced super-
oxide production [17], which is compatible with previous
studies [29, 31]. This might result from the reduced
expression and/or activity of vascular NADPH oxidases.
In endothelial cells, resveratrol attenuates oxidized low-
density lipoprotein-stimulated NADPH oxidase activity by
reducing the membrane translocation of Rac1, which is
required for the assembly of the active NADPH oxidase
complex [32]. Similarly, resveratrol restores endothelial
function in type II diabetes by inhibiting the TNFα-
induced activation of NADPH oxidase [15]. Resveratrol
treatment also decreases the expression of NADPH
oxidase (gp91phox, i.e. Nox2) [15]. Recent data from
our laboratory demonstrate that resveratrol also decreases
the expression of NADPH oxidase (Nox4) in endothelial
cells [33].
Resveratrol enhances the expression of antioxidant enzy-
mes Living organisms have developed a number of antiox-
idant enzyme systems to maintain their survival against
oxidative stress. Major cardiovascular enzymatic antioxi-
dants include superoxide dismutases (SOD) and catalase and
glutathione peroxidases (GPx) [34]. Resveratrol treatment
upregulates the expression of catalase and GPx1 in cultured
arteries [35]. We have recently shown that resveratrol
enhances the expression of SOD1 and GPx1 in endothelial
cells, and this mechanism contributes to the reduction of
endothelial oxidative stress by resveratrol [33].
Involvement of estrogen receptors and the question
of gender differences
Resveratrol activates nuclear and extranuclear estrogen
receptors (ER) [24, 36, 37]. Both ERα and ERβ are
expressed in vascular smooth muscle and endothelial cells
[38]. The rapid enzymatic activation of eNOS by resvera-
trol is mediated by plasma membrane-associated ER. In
bovine aortic endothelial cells, ERα and ERβ are both
involved in resveratrol-induced eNOS phosphorylation
[24]. In human umbilical vein endothelial cells (HUVEC),
however, the effect of resveratrol on eNOS phosphorylation
is mediated by ERα, but not ERβ [25].
In addition to the rapid non-genomic effect on eNOS
activity, resveratrol also enhances eNOS expression. Al-
though estrogen itself increases eNOS expression in an ER-
dependent manner [25, 39], the effect of resveratrol on
eNOS expression seems to be ER-independent [18], but
rather SIRT1-mediated [23].
Because vascular relaxation to estrogen shows gender-
dependent differences [31, 40], vascular effects of resveratrol
could be different between males and females. However, that
does not seem to be the case. In the study by Soylemez et al.,
resveratrol decreased superoxide production, increased plas-
ma nitrite/nitrate levels and enhanced acetylcholine-induced
relaxation in endothelium-denuded arteries from both male
and female rats [17]. No major gender differences were
found. This is compatible with a previous study demonstrat-
ing that resveratrol has similar protective effects on oxidative
DNA damage in male and female stroke-prone spontaneous-
ly hypertensive rats [41].
Taken together, a wide variety of signaling mechanisms
including transcriptional and post-translational effects con-
tribute to the improvement of endothelial function and
enhanced vasorelaxation produced by resveratrol.
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